---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-011174"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:30:38.387378+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics reports FY2024 net loss of $47.2M; NAVIGATE varices reduction in per-protocol

## Summary
- Net loss $47.2M ($0.76/sh) vs $44.5M ($0.74/sh) in 2023; R&D spend $36.6M up from $32.1M.
- Cash $15.1M at Dec 31, 2024; new $5M line of credit from chairman in March 2025; cash runway through Aug 2025.
- NAVIGATE trial: varices incidence reduced 49.3% (p=0.04) in per-protocol for belapectin 2 mg vs placebo.
- In US per-protocol patients, varices reduced 68.1% (p=0.02); ITT population did not reach significance.
- Additional biomarker data expected Q2 2025; belapectin has FDA Fast Track Designation for MASH cirrhosis.

## SEC filing metadata
- accession: 0001140361-25-011174
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036125011174/0001140361-25-011174-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036125011174/ef20046120_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-011174
- JSON: https://secwatch.observer/filing/0001140361-25-011174.json
- Plain text: https://secwatch.observer/filing/0001140361-25-011174.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.